GeoVax Labs, a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced on April 30 that Beijing- and Philadelphia-based Sino Biological, will be its exclusive supplier of SARS-CoV-2 (Covid-19) bioreagent research products.
Under the terms of the agreement, Sino Biological will provide key bioreagents such as recombinant proteins, antibodies and detection kits for use in Covid-19 vaccine development underway at GeoVax. Sino Biological will also obtain exclusive rights to research-use-only (RUO) reagents developed jointly by the companies.
Sino Biological was the first to market with mammalian cell-made Covid-19 viral recombinant proteins and offers a full range of these and other bioreagents to complement and aid in Covid-19 vaccine development and has the world’s largest selection of coronavirus research-grade products. GeoVax is at the forefront of development for a Covid-19 vaccine and its use of recombinant viruses to generate virus-like particles (VLPs) in vivo has demonstrated considerable immune response for other viruses in a number of human clinical trials.
- Commenting on the exclusive partnership, David A. Dodd, GeoVax Chairman & CEO stated, “We are delighted to establish this collaboration with Sino Biological related to our Covid-19 vaccine development program. Sino Biological is recognised as the research reagent industry leader in developing and providing Covid-19 bioreagent research products, as well as a leader throughout the bioreagent research industry. We look forward to further expansion of our relationship with Sino Biological, including our agreement related to research-use-only (RUO) reagents.”
- “GeoVax’s unique VLP-generation technology is exciting, and its commitment to the development of a vaccine for Covid-19 is inspiring. We at Sino Biological are honoured to be the exclusive provider of Covid-19-related research reagents to assist their vaccine development efforts”, says Dr Rob Burgess, Chief Business Officer for Sino Biological.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel proprietary vaccine platform (GV-MVA-VLP).
GeoVax’s current development programs are focused on preventive vaccines against COVID-19, HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against chronic Hepatitis B infections and multiple cancers.
Sino Biological is an international reagent supplier and service provider. The company specialises in recombinant antigen production and antibody development. It is also dedicated to virology and infectious disease research. Its newly launched ProVir collection is the world’s largest viral antigen bank, carrying over 800 products from 350 strains of viruses.